Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
New approaches and procedures for cancer treatment: Current perspectives
2021 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies
2021
Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation
2019 StandoutNobel
Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning
2009
Molecular imaging in drug development
2008 Standout
Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent
2014 StandoutNobel
Multicenter Photopheresis Intervention Trial in Early-Stage Mycosis Fungoides
2011
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation
2011
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis
2007
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
Mycosis Fungoides and Sezary Syndrome
2017
Photopheresis in the treatment of cutaneous T-cell lymphoma
2011
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
Prevention of VTE in Nonsurgical Patients
2012 Standout
3D Slicer as an image computing platform for the Quantitative Imaging Network
2012 Standout
Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphoma
2010
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients
2012
Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mycosis Fungoides and Sezary Syndrome: The InterLymph Non-Hodgkin Lymphoma Subtypes Project
2014
FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease
2006
Targeting apoptosis in cancer therapy
2020 Standout
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients
2006
Early therapeutic response assessment by18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure
2007
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017
2017
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
2005
Clinical molecular imaging with positron emission tomography
2006
Prevention of Venous Thromboembolism
2004 Standout
Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma
2010
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
2013
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
2009
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Microenvironmental regulation of metastasis
2008 Standout
Prevention of Venous Thromboembolism
2008 Standout
Drug Insight: thalidomide as a treatment for multiple myeloma
2005
Primary brain tumours in adults
2012 Standout
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Proteasome Inhibitors with Photocontrolled Activity
2014 StandoutNobel
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Overview of early response assessment in lymphoma with FDG-PET
2007
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations
2006
Chemotherapy-induced thrombosis
2006
FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma
2008
The thalidomide saga
2007
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
2005
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Role of Functional Imaging in the Management of Lymphoma
2011
2016 US lymphoid malignancy statistics by World Health Organization subtypes
2016 Standout
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Positron Emission Tomography As an Imaging Biomarker
2006
Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report
2010
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile
2018
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Interventions for treating oral mucositis for patients with cancer receiving treatment
2010
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
18F-FDG PET/CT Imaging In Oncology
2011
BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition
2018
CutaneousT ‐cell lymphoma: 2016 update on diagnosis, risk‐stratification, and management
2015
Transformed follicular non-Hodgkin lymphoma
2014
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
2006
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
A retrospective comparative outcome analysis following systemic therapy in M ycosis fungoides and S ezary syndrome
2016
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
2009
How I treat mycosis fungoides and Sézary syndrome
2016
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?
2016
Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
2007
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
2004
Works of Paul Fields being referenced
Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma
2018
Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial
2008
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
2005
A Randomised, Double-Blind, Placebo Controlled, Multicentre Trial of ATL-104, a Swallowable Mouthwash, in Patients with Oral Mucositis Following Peripheral Blood Stem Cell Transplantion (PBSCT).
2006
De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial
2013
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
2004
Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal
2010